{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:28:13Z","timestamp":1769153293445,"version":"3.49.0"},"reference-count":37,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.3201\/eid3101.230638","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:59:41Z","timestamp":1734483581000},"source":"Crossref","is-referenced-by-count":3,"title":["Research and Development of Medical Countermeasures for Emerging Infectious Diseases, China, 1990\u20132022"],"prefix":"10.3201","volume":"31","author":[{"given":"Jiyan","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangmu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3101.230638-202412171546-R1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/infdis\/jiad095","article-title":"Pandemic preparedness and response: lessons from COVID-19.","volume":"228","author":"Fauci","year":"2023","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3101.230638-202412171546-R2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s11427-017-9141-3","article-title":"China in action: national strategies to combat against emerging infectious diseases.","volume":"60","author":"Han","year":"2017","journal-title":"Sci China Life Sci"},{"key":"key-10.3201\/eid3101.230638-202412171546-R3","unstructured":"Policy Cures Research. Landscape of emerging infectious disease research and development: from pandemic response to pandemic resilience [cited 2023 Oct 20]. https:\/\/policy-cures-website-assets.s3.ap-southeast-2.amazonaws.com\/wp-content\/uploads\/2022\/06\/16191104\/2022-G-FINDER-EID-Report.pdf"},{"key":"key-10.3201\/eid3101.230638-202412171546-R4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S0140-6736(13)61046-6","article-title":"Mapping of available health research and development data: what\u2019s there, what\u2019s missing, and what role is there for a global observatory?","volume":"382","author":"R\u00f8ttingen","year":"2013","journal-title":"Lancet"},{"key":"key-10.3201\/eid3101.230638-202412171546-R5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2018.09.009","article-title":"The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts.","volume":"159","author":"Mehand","year":"2018","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3101.230638-202412171546-R6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/d41573-022-00058-6","article-title":"Evolution of innovative drug R&D in China.","volume":"21","author":"Li","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.3201\/eid3101.230638-202412171546-R7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/d41573-023-00119-4","article-title":"The R&D landscape for infectious disease vaccines.","volume":"22","author":"Yue","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.3201\/eid3101.230638-202412171546-R8","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.apsb.2022.08.004","article-title":"Evolution of drug regulations and regulatory innovation for anticancer drugs in China.","volume":"12","author":"Liu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"key-10.3201\/eid3101.230638-202412171546-R9","doi-asserted-by":"publisher","first-page":"e2225973","DOI":"10.1001\/jamanetworkopen.2022.25973","article-title":"Overall survival benefits of cancer drugs approved in China from 2005 to 2020.","volume":"5","author":"Zhang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"key-10.3201\/eid3101.230638-202412171546-R10","unstructured":"World Health Organization. Prequalified vaccines [cited 2023 Oct 20]. https:\/\/extranet.who.int\/prequal\/vaccines\/prequalified-vaccines"},{"key":"key-10.3201\/eid3101.230638-202412171546-R11","doi-asserted-by":"publisher","first-page":"e29016","DOI":"10.1002\/jmv.29016","article-title":"Development of a novel bispecific antibody GR1801 for rabies.","volume":"95","author":"Long","year":"2023","journal-title":"J Med Virol"},{"key":"key-10.3201\/eid3101.230638-202412171546-R12","doi-asserted-by":"publisher","first-page":"e029617","DOI":"10.1136\/bmjopen-2019-029617","article-title":"Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review.","volume":"9","author":"Mathebula","year":"2019","journal-title":"BMJ Open"},{"key":"key-10.3201\/eid3101.230638-202412171546-R13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrd.2016.200","article-title":"Regulatory watch: Innovative drug availability in China.","volume":"15","author":"Shao","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.3201\/eid3101.230638-202412171546-R14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-030-39819-4_7","article-title":"R&D for Emerging Infectious Diseases of Epidemic Potential: Sharing Risks and Benefits Through a New Coalition","volume":"82","author":"Gopinathan","year":"2020","journal-title":"Infectious Diseases in the New Millennium."},{"key":"key-10.3201\/eid3101.230638-202412171546-R15","doi-asserted-by":"publisher","first-page":"e1658","DOI":"10.1016\/S2214-109X(23)00328-5","article-title":"From private incentives to public health need: rethinking research and development for pandemic preparedness.","volume":"11","author":"Torreele","year":"2023","journal-title":"Lancet Glob Health"},{"key":"key-10.3201\/eid3101.230638-202412171546-R16","doi-asserted-by":"publisher","first-page":"632043","DOI":"10.3389\/fpubh.2021.632043","article-title":"Effects of pandemic outbreak on economies: evidence from business history context.","volume":"9","author":"Shang","year":"2021","journal-title":"Front Public Health"},{"key":"key-10.3201\/eid3101.230638-202412171546-R17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/d41573-020-00195-w","article-title":"Trends in oncology drug innovation in China.","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.3201\/eid3101.230638-202412171546-R18","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1016\/S2214-109X(20)30357-0","article-title":"The allocation of USdollar;105 billion in global funding from G20 countries for infectious disease research between 2000 and 2017: a content analysis of investments.","volume":"8","author":"Head","year":"2020","journal-title":"Lancet Glob Health"},{"key":"key-10.3201\/eid3101.230638-202412171546-R19","unstructured":"Australia\u2019s National Science Agency. Strengthening Australia\u2019s pandemic preparedness [cited 2023 Oct 20]. https:\/\/www.csiro.au\/en\/work-with-us\/services\/consultancy-strategic-advice-services\/csiro-futures\/health-and-biosecurity\/strengthening-australias-pandemic-preparedness"},{"key":"key-10.3201\/eid3101.230638-202412171546-R20","unstructured":"National Institute of Allery and Infectious Disease. NIAID pandemic preparedness plan [cited 2023 Oct 20]. https:\/\/www.niaid.nih.gov\/sites\/default\/files\/pandemic-preparedness-plan.pdf"},{"key":"key-10.3201\/eid3101.230638-202412171546-R21","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1016\/j.vaccine.2019.09.009","article-title":"UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments.","volume":"37","author":"Noad","year":"2019","journal-title":"Vaccine"},{"key":"key-10.3201\/eid3101.230638-202412171546-R22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11684-017-0605-9","article-title":"Landscape of emerging and re-emerging infectious diseases in China: impact of ecology, climate, and behavior.","volume":"12","author":"Liu","year":"2018","journal-title":"Front Med"},{"key":"key-10.3201\/eid3101.230638-202412171546-R23","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1038\/d41586-018-00542-3","article-title":"Biotech booms in China.","volume":"553","author":"Ellis","year":"2018","journal-title":"Nature"},{"key":"key-10.3201\/eid3101.230638-202412171546-R24","doi-asserted-by":"publisher","first-page":"583077","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development.","volume":"11","author":"Brisse","year":"2020","journal-title":"Front Immunol"},{"key":"key-10.3201\/eid3101.230638-202412171546-R25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.glohj.2019.11.002","article-title":"Health technology assessment in traditional Chinese medicine in China: current status, opportunities, and challenges.","volume":"3","author":"Yang","year":"2019","journal-title":"Glob Health J"},{"key":"key-10.3201\/eid3101.230638-202412171546-R26","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1001\/jama.2017.15033","article-title":"The critical role of biomedical research in pandemic preparedness.","volume":"318","author":"Marston","year":"2017","journal-title":"JAMA"},{"key":"key-10.3201\/eid3101.230638-202412171546-R27","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1073\/pnas.1701410114","article-title":"Emerging infectious diseases: A proactive approach.","volume":"114","author":"Bloom","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.3201\/eid3101.230638-202412171546-R28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hs.2019.0148","article-title":"Vaccine platform technologies: a potent tool for emerging infectious disease vaccine development.","volume":"18","author":"Adalja","year":"2020","journal-title":"Health Secur"},{"key":"key-10.3201\/eid3101.230638-202412171546-R29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41541-021-00290-y","article-title":"Promoting versatile vaccine development for emerging pandemics.","volume":"6","author":"Monrad","year":"2021","journal-title":"NPJ Vaccines"},{"key":"key-10.3201\/eid3101.230638-202412171546-R30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jgg.2021.02.006","article-title":"COVID-19 mRNA vaccines.","volume":"48","author":"Huang","year":"2021","journal-title":"J Genet Genomics"},{"key":"key-10.3201\/eid3101.230638-202412171546-R31","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"key-10.3201\/eid3101.230638-202412171546-R32","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/infdis\/jiac296","article-title":"Prototype pathogen approach for vaccine and monoclonal antibody development: a critical component of the NIAID plan for pandemic preparedness.","volume":"227","author":"Cassetti","year":"2023","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3101.230638-202412171546-R33","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1001\/jama.2020.9252","article-title":"Translating science on COVID-19 to improve clinical care and support the public health response.","volume":"323","author":"Del Rio","year":"2020","journal-title":"JAMA"},{"key":"key-10.3201\/eid3101.230638-202412171546-R34","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed.","volume":"382","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3101.230638-202412171546-R35","doi-asserted-by":"publisher","first-page":"14cm2","DOI":"10.1126\/scitranslmed.3000375","article-title":"Translational medicine policy issues in infectious disease.","volume":"2","author":"Fears","year":"2010","journal-title":"Sci Transl Med"},{"key":"key-10.3201\/eid3101.230638-202412171546-R36","doi-asserted-by":"publisher","first-page":"e1045","DOI":"10.1016\/S2214-109X(22)00206-6","article-title":"Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries.","volume":"10","author":"Sch\u00e4ferhoff","year":"2022","journal-title":"Lancet Glob Health"},{"key":"key-10.3201\/eid3101.230638-202412171546-R37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles.","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl Med Commun"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/31\/1\/23-0638_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T02:09:10Z","timestamp":1735524550000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/31\/1\/23-0638_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3101.230638","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}